文献速递眼底病与葡萄膜炎

英夫利西单抗相比阿达木单抗降低威胁视力性葡萄膜炎的复发率:一项330例患者的多中心研究

Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
PubMed 文献 · Am J Ophthalmol · 2022-02-13

这项观察性回顾性多中心研究纳入330例接受英夫利西单抗(IFX)或阿达木单抗(ADA)治疗的威胁视力性非感染性葡萄膜炎(NIU)患者,比较复发率。引入生物制剂后6个月估计复发率为13%(95%CI=0.009-0.16),IFX较ADA与更低的复发风险相关(HR=0.52,95%CI=0.36-0.77,P=.001),两者在完全缓解率和激素节约效应方面相当。

要点

  • IFX较ADA与更低的复发风险相关(HR=0.52,95%CI=0.36-0.77,P=.001)。
  • 引入生物制剂后6个月估计复发率为13%(95%CI=0.009-0.16)。
  • ADA与IFX在NIU完全缓解率及激素节约效应方面相当。

核心结论

  • 在威胁视力性NIU中,IFX似乎较ADA与更低的复发率相关。

研究设计与样本

  • 观察性回顾性多中心研究,共纳入330例威胁视力性NIU患者(中位年龄36岁,四分位距27-54,45.2%为男性)。
  • 患者接受抗TNF-α药物治疗:IFX静脉给药5 mg/kg,在第0、2、6周及之后每4至6周给药;或ADA皮下给药80 mg后每2周40 mg。
  • 数据从患者病历中回顾性获取,主要结局指标为复发率、NIU完全缓解、激素节约效应及安全性。

主要发现

  • 葡萄膜炎主要病因包括白塞病(27%)、特发性幼年关节炎(5.8%)和结节病(5.5%)。
  • 引入生物制剂后6个月估计复发率为13%(95%CI=0.009-0.16)。
  • IFX较ADA与更低的复发风险相关(HR=0.52,95%CI=0.36-0.77,P=.001)。
  • ADA与IFX在NIU完全缓解率及激素节约效应方面相当。
  • 白塞病较其他NIU病因在接受抗TNF-α药物治疗时与更高的完全缓解几率(HR=2.04,95%CI=1.16-3.60,P=.01)和更低的复发率(HR=0.53,95%CI=0.33-0.85,P=.009)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the relapse rate of sight-threatening noninfectious uveitis (NIU) in patients treated with infliximab (IFX) or adalimumab (ADA). DESIGN: Observational retrospective multicenter study. METHODS: A total of 330 patients (median age, 36 years; interquartile range, 27-54), 45.2% men) with sight-threatening NIU (ie, retinal vasculitis and/or macular edema) treated with anti-tumor necrosis factor [TNF]-α agents (IFX intravenously at 5 mg/kg at weeks 0, 2, 6, and every 4 to 6 weeks or ADA subcutaneously at 80 mg, then 40 mg every 2 weeks). Data were obtained retrospectively from patients' medical records. Main outcome measures were relapse rate, complete response of NIU, corticosteroid sparing effect, and safety. RESULTS: Main etiologies of uveitis included Behçet disease (27%), idiopathic juvenile arthritis (5.8%), and sarcoidosis (5.5%). The estimated relapse rate at 6 months after introduction of biological agents was 13% (95% CI = 0.009-0.16). IFX was associated with less relapse risk than ADA (hazard ratio [HR] = 0.52, 95% CI = 0.36- 0.77, P = .001). ADA and IFX were comparable in terms of complete response rate of NIU as well as corticosteroid-sparing effect. Behçet disease was associated with higher odds of complete response (HR = 2.04, 95% CI = 1.16 -3.60, P = .01] and lower relapse rate (HR = 0.53, 95% CI = 0.33-0.85, P = .009) than other causes of NIU with anti-TNF-α agents. CONCLUSIONS: In sight-threatening NIU, IFX seems to be associated with a lower relapse rate than ADA.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Maalouf G, Andrillon A, Leclercq M, et al. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients. Am J Ophthalmol. 2022. PMID: 35172172. doi:10.1016/j.ajo.2022.02.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。